[HTML][HTML] Real-world outcomes of hodgkin lymphoma: a multi-centric registry from India
D Bhurani, R Nair, S Rajappa, SA Rao… - Frontiers in …, 2022 - frontiersin.org
Background Hodgkin's lymphoma (HL) is one of the most curable malignancies with a 5-
year survival of over 80%. Most published literature from low-middle income countries …
year survival of over 80%. Most published literature from low-middle income countries …
Evaluation of late effects during a 21-year follow-up of pediatric Hodgkin lymphoma survivors: Experience of a pediatric cancer center in Turkey, as a developing …
N Tacyildiz, HM Cakmak, E Unal… - Indian Journal of …, 2024 - journals.lww.com
Background: Long-term survivors of Hodgkin lymphoma (HL) are at risk of developing a
range of late effects, with a second malignant neoplasm and cardiovascular diseases being …
range of late effects, with a second malignant neoplasm and cardiovascular diseases being …
[HTML][HTML] Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
SC Macapagal, H Lee, JA Jabbar, AC Fjorden… - Cureus, 2022 - ncbi.nlm.nih.gov
The central dilemma in treating patients with refractory or relapsed classical Hodgkin
lymphoma (RRHL) is the developed resistance to chemotherapy. In recent years, significant …
lymphoma (RRHL) is the developed resistance to chemotherapy. In recent years, significant …